Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense antivirals.

J Goodchild1

  • 1Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts.

Antisense Research and Development
|January 1, 1991
PubMed
Summary

Antisense oligonucleotides show promise for antiviral therapies, particularly against HIV-1. Research explores their design, metabolism, and modification, alongside potential ribozyme applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.

British journal of clinical pharmacology·2025
Same author

Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA.

Antisense & nucleic acid drug development·2001
Same author

Hammerhead ribozymes: biochemical and chemical considerations.

Current opinion in molecular therapeutics·2001
Same author

Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.

Cancer immunology, immunotherapy : CII·1999
Same author

Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis.

Nucleic acids research·1998
Same author

In vitro optimization of truncated stem-loop II variants of the hammerhead ribozyme for cleavage in low concentrations of magnesium under non-turnover conditions.

RNA (New York, N.Y.)·1997

Area of Science:

  • Molecular Biology
  • Antiviral Therapeutics
  • Oligonucleotide Chemistry

Background:

  • Antisense oligonucleotides (ASOs) represent a novel therapeutic strategy for viral infections.
  • Human Immunodeficiency Virus type 1 (HIV-1) remains a significant global health challenge.
  • Targeted nucleic acid-based therapies offer potential for specific viral inhibition.

Purpose of the Study:

  • To review the antiviral applications of antisense oligonucleotides.
  • To present original research on inhibiting HIV-1 using ASOs.
  • To discuss future directions including ribozyme technology.

Main Methods:

  • Design principles for effective antisense oligonucleotides.
  • Investigation of oligonucleotide metabolism and stability in biological systems.
  • Chemical modifications to enhance ASO efficacy and delivery.

Main Results:

  • Demonstrated inhibition of HIV-1 replication using ASOs.
  • Characterization of ASO pharmacokinetics and pharmacodynamics.
  • Evaluation of ASO design parameters for antiviral activity.

Conclusions:

  • Antisense oligonucleotides are a viable approach for antiviral drug development.
  • Further research into ASO design and modification can optimize efficacy against HIV-1.
  • Ribozymes present a complementary or alternative strategy for future antiviral therapies.

Related Experiment Videos